InMed Pharmaceuticals Inc 2026年季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes☐No☒ On February 9, 2026, there were 2,919,186 shares of the registrant’s common shares, no par value (the “Common Shares”),outstanding. INDEXPagePART I – FINANCIAL INFORMATION1ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS1ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS19ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK29ITEM 4. CONTROLS AND PROCEDURES29PART II – OTHER INFORMATIONITEM 1. LEGAL PROCEEDINGS30ITEM 1A. RISK FACTORS30ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS31ITEM 3. DEFAULTS UPON SENIOR SECURITIES31ITEM 4. MINE SAFETY DISCLOSURE31ITEM 5. OTHER INFORMATION31ITEM 6. EXHIBITS31SIGNATURES32i CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains “forward-looking statements” within the meaning of theUnited States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicableCanadian securities law, which include but are not limited to statements with respect to the Company’s anticipated results and progress “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will”, “would”, and similar expressions thatconvey uncertainty of future events or outcomes to identify these forward-looking statements. Any statements contained herein that arenot statements of historical facts may be deemed to be forward-looking statements. Some of the important risks and uncertainties thatcould materially affect forward-looking statements are described further under IA. “Risk Factors” in our Annual Report on Form 10-Kfor the year ended June 30, 2025, which was originally filed with the SEC on September 23, 2025 (the “2025 Annual Report”), Item ●Our ability to stem operating losses and our ability to obtain additional financing to fund our operations; ●The revenues of BayMedica, LLC (“BayMedica”) and the commercial viability of its product portfolio, as well as thepotential material adverse impact of recent legislation in the United States on BayMedica’s commercial business and itsinventory of rare, non-intoxicating cannabinoids; ●Our ability to effectively research, develop, manufacture and commercialize pharmaceutical drug candidates that will treatdiseases with high unmet medical needs; ●The continued optimization of key, proprietary manufacturing approaches and technologies; ●Our ability to commercialize and, where required, register products in the pharmaceutical R&D programs (“ProductCandidates”) and those targeted to the health and wellness sector (“Products”) in the United States and other jurisdictions; ●Our success in initiating discussions with potential partners for licensing various aspects of our Product Candidates; ●Ourability to successfully access existing manufacturing capacity via leases with third-parties or to transfer ourmanufacturing processes to contract manufacturing organizations; ●Our belief that manufacturing approaches that we are developing are robust and effective and will result in commerciallyviable yields of cannabinoids and will be a significant improvement upon existing manufacturing platforms; ●Our ability to successfully scale up our IntegraSyn approach to cannabinoid manufacturing. We have created geneticallyengineered microbes that produce proprietary enzymes, which are then used to optimize subsequent biotransformationreactions or other cost-effective manufacturing approaches so that it may be a potential manufacturing method in the future ●The success of the key next steps in our manufacturing approaches, including continuing efforts to diversify the number ofproducts produced, scaling-up the processes to larger vessels and identifying external vendors to assist in the commercial ●Our ability to successfully make determinations as to which research and development programs to continue based on severalstrategic factors; ●Our ability to continue to outsource the majority of our research and development activities through scientific collaborationagre